ecteinascidin 743 has been researched along with Carcinoma, Ovarian Epithelial in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 8 (61.54) | 24.3611 |
| 2020's | 5 (38.46) | 2.80 |
| Authors | Studies |
|---|---|
| Albert, S; Bessede, A; Blay, JY; Brahmi, M; Chakiba, C; Cousin, S; Croce, S; Floquet, A; Giraud, A; Guégan, JP; Italiano, A; Kind, M; Mathoulin-Pelissier, S; Perret, R; Pulido, M; Ray-Coquard, I; Toulmonde, M; Toulza, E | 1 |
| Coukos, G; Digklia, A; Homicsko, K | 1 |
| Avesani, G; Boccia, SM; Corrado, G; Fagotti, A; Marchetti, C; Scambia, G; Tiberi, G; Vertechy, L | 1 |
| Aglietta, M; Arcangeli, V; Barretina-Ginesta, MP; Benedetti Panici, P; Berger, R; Biagioli, E; Bologna, A; Chekerov, R; Churruca Galaz, C; Colombo, N; D'Incalci, M; De Giorgi, U; DeCensi, A; Deryal, M; Fossati, R; Funari, G; Gadducci, A; Heinzelmann-Schwarz, V; Herbertson, R; Iglesias, M; Mäenpää, J; Mirza, MR; Montes, A; Nyvang, GB; Ottevanger, NB; Pardo, B; Poveda, A; Riniker, S; Romeo, M; Rubio-Pérez, MJ; Rulli, E; Sehouli, J; Sessa, C; Tasca, G; Tognon, G; Tsibulak, I; Vergote, I; Westermann, A; Wimberger, P; Zamagni, C; Zola, P | 1 |
| Cao, D; Chen, H; Kossinna, P; Li, Q; Lin, C; Lin, J; Liu, GR; Liu, H; Liu, SL; Luo, Y; Wang, J; Wang, P; Wang, X; Wang, Y; Xie, K; Xu, M; Xu, X; Yang, H; Yang, J; Zeng, Z; Zhang, MC; Zhang, XH; Zhu, S | 1 |
| Baldoni, A; Biagioli, E; Colombo, N; D'Incalci, M; Farina, G; Ferrero, A; Fossati, R; Frezzini, S; Galli, F; Gerardi, C; Lissoni, AA; Negri, E; Palluzzi, E; Pesenti Gritti, A; Poli, D; Rubino, D; Rulli, E; Scambia, G; Tognon, G; Torri, V; Zaccarelli, E | 1 |
| Bonetti, A; Giuliani, J | 1 |
| C Cecere, S; Du Bois, A; Harter, P; Heitz, F; Pignata, S | 1 |
| Arenare, L; Califano, D; Cecere, SC; Di Napoli, M; Losito, NS; Orditura, M; Paciolla, I; Pignata, S; Pisano, C; Setola, SV; Ventriglia, J | 1 |
| Bazaeva, IIa; Cherkasova, MV; Gorbunova, VA; Khokhlova, SV; Limareva, SV; Orel, NF | 1 |
| López-Guerrero, JA; Poveda, A; Romero, I | 1 |
| Herzog, TJ; Teplinsky, E | 1 |
| Herzog, TJ; Kaye, SB; Krasner, CN; Monk, BJ; Muggia, FM; Parekh, TV; Park, YC; Poveda, AM; Pujade-Lauraine, E; Vermorken, JB | 1 |
5 review(s) available for ecteinascidin 743 and Carcinoma, Ovarian Epithelial
| Article | Year |
|---|---|
Treatment of recurrent ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Ovarian Epithelial; Clinical Trials, Phase III as Topic; Dioxoles; Disease-Free Survival; Doxorubicin; Female; Humans; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Polyethylene Glycols; Prospective Studies; Randomized Controlled Trials as Topic; Retrospective Studies; Tetrahydroisoquinolines; Trabectedin | 2017 |
Trabectedin in Ovarian Cancer: is it now a Standard of Care?
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Standard of Care; Trabectedin | 2018 |
[Which patients with ovarian cancer shows the combination of trabectedin with pegylated liposomal doxorubicin].
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Carcinoma, Ovarian Epithelial; Dioxoles; Doxorubicin; Drug Therapy, Combination; Female; Humans; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Patient Selection; Polyethylene Glycols; Tetrahydroisoquinolines; Trabectedin; Treatment Outcome | 2013 |
Trabectedin therapy as an emerging treatment strategy for recurrent platinum-sensitive ovarian cancer.
Topics: Antineoplastic Agents, Alkylating; Carcinoma, Ovarian Epithelial; Clinical Trials as Topic; Dioxoles; DNA Damage; Doxorubicin; Female; Humans; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Polyethylene Glycols; Tetrahydroisoquinolines; Trabectedin; Tumor Microenvironment | 2015 |
The efficacy of trabectedin in treating ovarian cancer.
Topics: Antineoplastic Agents, Alkylating; Carcinoma, Ovarian Epithelial; Clinical Trials, Phase III as Topic; Dioxoles; Disease-Free Survival; Doxorubicin; Drug Discovery; Female; Humans; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Neutropenia; Ovarian Neoplasms; Polyethylene Glycols; Tetrahydroisoquinolines; Trabectedin; Tumor Microenvironment | 2017 |
3 trial(s) available for ecteinascidin 743 and Carcinoma, Ovarian Epithelial
| Article | Year |
|---|---|
INOVATYON/ ENGOT-ov5 study: Randomized phase III international study comparing trabectedin/pegylated liposomal doxorubicin (PLD) followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 month
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Doxorubicin; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Polyethylene Glycols; Trabectedin | 2023 |
Multicenter, randomised, open-label, non-comparative phase 2 trial on the efficacy and safety of the combination of bevacizumab and trabectedin with or without carboplatin in women with partially platinum-sensitive recurrent ovarian cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Ovarian Neoplasms; Progression-Free Survival; Survival Rate; Trabectedin | 2019 |
Trabectedin plus pegylated liposomal doxorubicin (PLD) versus PLD in recurrent ovarian cancer: overall survival analysis.
Topics: Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Dioxoles; Disease-Free Survival; Doxorubicin; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Polyethylene Glycols; Survival Analysis; Tetrahydroisoquinolines; Trabectedin | 2012 |
5 other study(ies) available for ecteinascidin 743 and Carcinoma, Ovarian Epithelial
| Article | Year |
|---|---|
Trabectedin plus Durvalumab in Patients with Advanced Pretreated Soft Tissue Sarcoma and Ovarian Carcinoma (TRAMUNE): An Open-Label, Multicenter Phase Ib Study.
Topics: Antibodies, Monoclonal; Carcinoma, Ovarian Epithelial; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Sarcoma; Soft Tissue Neoplasms; Trabectedin | 2022 |
Trabectedin and Durvalumab Combination Is Feasible and Active in Relapsing Ovarian Cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Dioxoles; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Sarcoma; Soft Tissue Neoplasms; Tetrahydroisoquinolines; Trabectedin | 2022 |
Trabectedin plus pegylated liposomal doxorubicin in patients with disease progression after PARP inhibitor maintenance: a real-life case-control study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Case-Control Studies; Disease Progression; Doxorubicin; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors; Polyethylene Glycols; Trabectedin | 2023 |
Enterolactone and trabectedin suppress epithelial ovarian cancer synergistically via upregulating THBS1.
Topics: Animals; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cell Proliferation; Endothelial Cells; Female; Humans; Mice; Ovarian Neoplasms; Thrombospondin 1; Trabectedin; Vascular Endothelial Growth Factor A | 2023 |
The Pharmacological Costs of Second-Line Treatments for Recurrent Ovarian Cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Deoxycytidine; Dioxoles; Disease-Free Survival; Doxorubicin; Drug Costs; European Union; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Polyethylene Glycols; Randomized Controlled Trials as Topic; Survival Rate; Tetrahydroisoquinolines; Trabectedin | 2017 |